Monopar Therapeutics (NASDAQ:MNPR) Receives Buy Rating from BTIG Research

BTIG Research reiterated their buy rating on shares of Monopar Therapeutics (NASDAQ:MNPR) in a research note issued to investors on Monday morning,Benzinga reports. The brokerage currently has a $104.00 price objective on the stock.

A number of other equities research analysts have also issued reports on the company. Morgan Stanley began coverage on Monopar Therapeutics in a research report on Friday, January 9th. They set an “overweight” rating and a $115.00 target price on the stock. Chardan Capital restated a “buy” rating and set a $100.00 price objective on shares of Monopar Therapeutics in a report on Thursday, January 29th. Leerink Partners started coverage on shares of Monopar Therapeutics in a report on Monday, November 10th. They issued an “outperform” rating and a $115.00 target price for the company. Raymond James Financial downgraded shares of Monopar Therapeutics from a “strong-buy” rating to an “outperform” rating and dropped their target price for the stock from $142.00 to $123.00 in a research report on Friday, November 14th. Finally, Wall Street Zen lowered shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Monopar Therapeutics has an average rating of “Buy” and a consensus price target of $107.00.

Monopar Therapeutics Stock Performance

Monopar Therapeutics stock opened at $55.80 on Monday. The firm has a market cap of $372.74 million, a price-to-earnings ratio of -16.22 and a beta of 1.52. Monopar Therapeutics has a 1 year low of $26.06 and a 1 year high of $105.00. The firm’s 50 day moving average price is $64.60 and its two-hundred day moving average price is $67.40.

Insiders Place Their Bets

In other Monopar Therapeutics news, CFO Quan Anh Vu acquired 1,500 shares of the business’s stock in a transaction that occurred on Friday, December 26th. The shares were purchased at an average price of $69.95 per share, with a total value of $104,925.00. Following the completion of the transaction, the chief financial officer owned 1,500 shares in the company, valued at $104,925. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 20.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Monopar Therapeutics

Several hedge funds have recently bought and sold shares of MNPR. AlphaQuest LLC increased its holdings in shares of Monopar Therapeutics by 8.5% during the 3rd quarter. AlphaQuest LLC now owns 1,935 shares of the company’s stock valued at $158,000 after acquiring an additional 151 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in Monopar Therapeutics during the third quarter worth approximately $28,000. BNP Paribas Financial Markets boosted its position in Monopar Therapeutics by 100.6% during the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after purchasing an additional 349 shares during the period. Police & Firemen s Retirement System of New Jersey acquired a new position in Monopar Therapeutics during the second quarter valued at approximately $34,000. Finally, Meeder Asset Management Inc. bought a new position in shares of Monopar Therapeutics in the fourth quarter valued at approximately $65,000. 1.83% of the stock is owned by institutional investors and hedge funds.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.